PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
撤稿通知：“通过负载 siRNA 的纳米颗粒同时沉默 A2aR 和 PD-1 免疫检查点，增强树突状细胞疫苗在肿瘤实验模型中的免疫治疗潜力” [Life Sci. 288 (2022) 120166]
英文原题：Retraction notice to "Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models" [Life Sci. 288 (2022) 120166].
查看英文原题
Retraction notice to "Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models" [Life Sci. 288 (2022) 120166].
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
摘要
这条来源本身就没有摘要（PubMed 未提供），不是「还没翻译」。可以点最下面的「在 PubMed 查看」打开原文献页面。
论文信息
- 作者
- Kiani FK、Izadi S、Dezfouli EA、Ebrahimi F、Mohammadi M、Chalajour H、Bulus MM、Esfahani MN
- 第一作者单位
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.Iran
- 通讯作者单位
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.Iran
- 文献类型
- 撤稿声明
- 期刊
- Life sciences2024 Aug 1
- 原文标识
- PubMed 38851943 · DOI 10.1016/j.lfs.2024.122775